Dr. Edwin Klumper has announced that he will step down from his role as CEO of Lytix Biopharma because of early retirement. The board has decided to promote Head of R&D Øystein Rekdal to the position of CEO from September 11, 2019. Dr. Klumper has agreed to assist the company with consultancy services until 30th of August 2020 as needed.

Director of the board Espen Johnsen says:

“On the behalf of the board I wish to thank Dr. Klumper for all his efforts for Lytix Biopharma over the past years, during which time he was very active with a lot of travelling. At the same time, we appreciate that Dr. Klumper will still be accessible for advice and consultancy services for the company”.

Dr. Rekdal is one of the founders of Lytix Biopharma and its portfolio including LTX-315 and LTX-401. Dr. Rekdal served as a CEO of Lytix Biopharma in the first years after the company was established and has, until now served as CSO and Head of R&D. Dr. Rekdal has world leading expertise on oncolytic peptides and he possesses a broad international network within immuno-oncology. Dr. Rekdal knows the company very well, the technological platform, the organization and the future challenges. Rekdal will immediately accede to the role of CEO.

Espen Johnsen continues:

“The appointment of Øystein Rekdal as acting CEO will secure continuity for the company`s.  Øystein knows the history of the company as well as our technology and development plans very well. We are sure he will use all his experience from the company in the CEO position. We are very grateful that Øystein is willing to serve as CEO and are looking very much forward to collaborate with him.

For more information contact:

Øystein Rekdal, CEO                       

E-mail: øystein.rekdal@lytixbiopharma.com

Espen Johnsen, Chairman            

E-mail: espen.johnsen@taveinvest.com

About Lytix Biopharma AS

Lytix Biopharma: Based in Oslo, Norway, Lytix Biopharma is a clinical stage biotech company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – the nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic peptide with the potential to personalize immunotherapy.